FDA Brief

Warning letters Drugs

FDA warning letter to

BioLyte Laboratories, LLC

High riskIssued Mar 18, 2021Posted Mar 22, 2021Division of Pharmaceutical Quality Operations III

FDA cited BioLyte Laboratories for manufacturing failures and unapproved silver, CBD, and magnesium drug products.

What happened

FDA inspected BioLyte’s drug manufacturing facility in Grand Rapids, MI, from December 9 to 18, 2019 and on February 13, 2020, and reviewed the company’s January 9, 2020 response to the inspection findings. FDA also reviewed product labeling, including websites listed on the labels. FDA found failures in current good manufacturing practice (CGMP, the quality rules for drug manufacturing)—including batch testing, component identity testing, and stability data—and found that silver, pain, CBD, and magnesium products were marketed as unapproved new drugs and were misbranded (illegally labeled or marketed).

What FDA found

  1. The company released OTC topical drugs without testing each batch for identity and strength of active ingredients, such as menthol 4%.

    21 CFR 211.165(a)
  2. The company did not perform identity testing on each incoming drug component and did not validate supplier test results reported on certificates of analysis.

    21 CFR 211.84(d)(1) and (2)
  3. The company lacked stability data to support the 3-year expiration date for its OTC Pain Relief drug product.

    21 CFR 211.166(a)
  4. The company marketed silver, pain, CBD, and magnesium products as drugs with claims to treat wounds, infections, pain, and other conditions without FDA-approved applications.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  5. The products were misbranded, meaning FDA says their labeling or marketing violated the law.

    FD&C Act section 502, 21 U.S.C. 352
  6. The Magnesium Oil Spray and CBD-labeled pain products did not meet conditions for marketing as nonprescription drugs without an approved application.

    FD&C Act section 505G; 21 CFR 330.1(e)

What FDA wants

FDA tells BioLyte to correct the violations and provide detailed testing, supplier qualification, retain-sample, and stability plans, and to address the unapproved new drug and misbranding charges. No response deadline is stated in the provided letter.

Who should pay attention

  • retailers and distributors selling silver, CBD, homeopathic, or magnesium products
  • brands that rely on contract manufacturers’ certificates of analysis
  • consumers using unapproved topical wound-care or pain products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk